MedPath

High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol

Not Applicable
Completed
Conditions
Hypoxia
Esophagus Cancer
Adverse Event
Gastric Cancer
Interventions
Device: High-flow nasal cannula oxygenation
Registration Number
NCT03332433
Lead Sponsor
RenJi Hospital
Brief Summary

Hypoxia is the most common adverse events during sedated gastroscopy. In present study, high-flow nasal cannula oxygenation will be utilized in order to reduce the hypoxia. At the same time the feasibility and safety will be evaluated.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2034
Inclusion Criteria
  • patients undergoing gastroscope
  • age over 18 years old
  • Signed informed consent form
Exclusion Criteria
  • Coagulation disorders or a tendency of nose bleeding;
  • An episode/exacerbation of congestive heart failure (CHF) that requires a change in medication, diet or hospitalization from any cause in the last 6 months;
  • Severe aortic stenosis or mitral stenosis;
  • Cardiac surgery involving thoracotomy (e.g., coronary artery bypass graft (CABG), valve replacement surgery) in the last 6 months;
  • Acute myocardial infarction in the last 6 months;
  • Acute arrhythmia (including any tachycardia - or bradycardia) with hemodynamic instability;
  • Diagnosed chronic obstructive pulmonary disease or current other acute or chronic lung disease requiring supplemental chronic or intermittent oxygen therapy);
  • Increased intracranial pressure;
  • ASA >III;
  • Mouth, nose, or throat infection;
  • Fever, defined as core body temperature > 37.5oC ;
  • Pregnancy, breastfeeding or positive pregnancy test
  • Emergency procedure

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
High-flow nasal cannula groupHigh-flow nasal cannula oxygenationOxygen(up to 60L/min) supplied with high-flow nasal cannula
Primary Outcome Measures
NameTimeMethod
Incidence of hypoxiaPatients will be followed for the duration of hospital stay, an expected average of 2 hours

(75% ≤ SpO2 \< 90% for \<60 s)

Secondary Outcome Measures
NameTimeMethod
Other adverse eventsPatients will be followed for the duration of hospital stay, an expected average of 2 hours

Other adverse events include other adverse events recorded by tools proposed by the World Society of Intravenous Anesthesia International Sedation Task Force and HFNC supportive oxygen therapy-related adverse events.

Incidence of subclinical respiratory depressionPatients will be followed for the duration of hospital stay, an expected average of 2 hours

(90% ≤ SpO2 \< 95%)

Incidence of severe hypoxiaPatients will be followed for the duration of hospital stay, an expected average of 2 hours

(SpO2 \< 75% for any duration or 75% ≤ SpO2 \< 90% for \>/=60 s)

Trial Locations

Locations (3)

Shanghai Tongji Hospital

🇨🇳

Shanghai, Shanghai, China

Renji hospital, School of Medicine, Shanghai Jiaotong University

🇨🇳

Shanghai, Shanghai, China

Shanghai Pudong New Area People's Hospital

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath